A coronavirus vaccine (COVID 19) is being developed by Altimmune for prevention against COVID-2019 infections. Altimmune is using its proprietary RespirVec platform to develop the COVID 19 candidate. The vaccine is designed to provide systemic immunity following a single intranasal dose. The intranasal delivery directs the immune response to the site of initial viral attack and provides systemic protection. Preclinical trial is underway in the US.
The RespirVec platform is comprised of intranasal delivery of replication-deficient adenoviruses. The adenovectored pathogen sequences elicits a rapid as well as long-term immune protection. The technology, includes intracellular expression of the vaccine antigen for authentic immune presentation, mobilisation of the innate, cellular and mucosal immune systems instead of just the antibody-based response triggered by conventional injectable vaccines, a more durable antibody response, self-adjuvanting adenovector delivery system with the potential to improve immunogenicity.
Altimmune is actively seeking partners for the development of intranasal coronavirus vaccine (Altimmune pipeline, March 2020).
In March 2020, Altimmune entered into an agreement with University of Alabama at Birmingham (UAB) for the development of intranasal COVID-19 vaccine, AdCOVID. Under the terms of agreement, initially Altimmune will work with UAB investigators to perform preclinical studies and to analyse the vaccine immunogenicity. 
Key Development Milestones
As of May 2020, Altimmune in collaboration with the University of Alabama at Birmingham (UAB) initiated preclinical testing of COVID-19 vaccine 
As of February 2020, the design and synthesis of the vaccine was completed. Altimmune announced its intention to advance it towards animal testing and manufacturing  .